Establishment of a treatment for advanced hepatocellular carcinoma using a tri-functional specific antibody

由于晚期肝细胞癌的治疗方法尚未确定，我们一直在进行这项研究，目的是开发治疗性抗体作为理想的治疗剂。我们发现干扰素-α/β可诱导几种人肝癌细胞成纤维细胞生长因子受体-1的表达上调。基于这一结果，我们制备了几种抗FGFR-1的单抗(MoAbs)。我们揭示了抗FGFR-1单抗和干扰素-α/β联合治疗人肝癌细胞的体内外疗效。这种抗体治疗的目的是为了更有效的抗癌作用，我们对这种抗体进行了分子改造，并在本研究中建立了一种三功能的特异性抗体。

For advanced hepatocellular carcinoma has not been established at all treatments, we' ve been doing this research for the purpose of development of therapeutic antibodies as ideal therapeutic agents. We have shown that interferon(IFN)-α/βinduced the up-regulation of fibroblast growth factor receptor-1(FGFR-1) expression in several human liver cancer cells. Based on this result, we have created several anti-FGFR-1 monoclonal antibodies(MoAbs). We revealed that the efficacy of combined treatment with anti-FGFR-1 MoAb and interferon-α/βin human liver cancer cells in vitro and in vivo. The aim of this antibody therapy is more potent anti-cancer effects, we performed molecular alterations of this antibody, and established a tri-functional specific antibody in this study.